Heidelberg Pharma AG Stock
Price
Target price
€2.96
€2.96
-0.340%
-0.01
-0.340%
-
17:06 / Tradegate
WKN: A11QVV / Name: Heidelberg Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Heidelberg Pharma AG Stock
Heidelberg Pharma AG shows a slight decrease today, losing -€0.010 (-0.340%) compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Heidelberg Pharma AG stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | -0.340% | -0.669% | -3.883% | -24.041% | -19.293% | -55.472% | -3.571% |
| Nanorepro AG | -6.350% | -1.093% | 4.323% | -14.623% | -12.136% | -78.978% | 52.101% |
| CytoTools AG | 28.180% | -2.804% | 27.607% | -81.913% | -45.974% | -97.650% | -96.604% |
| Vivoryon Therapeutics N.V. | -3.330% | 14.225% | 58.398% | -95.837% | -89.913% | -94.407% | -96.219% |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101